“…As such, this group has been retained in oxazolidinones, having undergone significant development efforts (eperezolid, RWJ-416457, and radezolid). Although many other heterocyclic substitutions were poorly tolerated (58), certain analogs, such as the 1,2,3-triazoles from AstraZeneca ("compound 2" [57] and "example 1" [24]) and Kyorin/Merck (AM-7359) (37,52) showed good activity, possibly due to different binding modes in the ribosome (57). Thus, in addition to the 1,2,3-triazole, there is now significant interest in other A-ring C-5 substituents, such as the hydroxymethyl (torezolid) group.…”